News

Advanced Biological Laboratories (ABL) S.A. and SafeBlood BioAnalytica S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Greece. See current channel partners.

ABL is pleased to announce the immediate available of two new DeepChek® Assays intended to be used for: Determining eligibility for CCR5 antagonist treatment in patients infected with human immunodeficiency virus 1 (HIV-1) – DeepChek®-HIV V3 Loop/Tropism Assay HBV genotyping, drug resistance a…

South Africa/Luxembourg, Tuesday, 4 July 2017: The Foundation for Professional Development (FPD) Group and Right to Care Group, joined forces to bring their healthcare technology under one umbrella for the advancement of health outcomes in developing countries. The new organisation which will house…

Advanced Biological Laboratories (ABL) S.A. and Kron Científica e Industrial S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Guatemala. See current channel partners.

Fédialis Médica a le plaisir de vous informer que les hôpitaux de la Pitié-Salpêtrière à Paris, ainsi que le ​CHU de ​Fort de France en Martinique utilisent notre logiciel CeGInaDis (version CeGIDD du logiciel NADIS) pour leurs activités de routine CeGIDD.

Advanced Biological Laboratories (ABL) S.A. and BADER SULTAN & BROTHERS CO W.L.L are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Kuwait. See current channel partners.

I’m interested!

Fédialis Médica a le plaisir de vous informer de la signature d’un partenariat avec l’AFRAVIH (www.afravih.org/) dans le but de tester l’utilisation du dossier médical informatisé NADIS pour le suivi et la prise en charge de patients vivant avec une pathologie chronique (VIH, hépatite, t…

ABL is pleased to announce the official release of its SeqHepB v6 interpretation system & database. Dedicated to the management of Viral Hepatitis B (HBV) sequencing data, the software can handle Capillary Electrophoresis or Next Generation Sequencing data, performs genotyping and mutation detec…

  ABL is pleased to announce the renewal and the extension of the Reseller rights given to ThermoFisher to promote ABL’s Capillary Electrophoresis sequencing data analysis software (ViroScore®), on a worldwide basis (except Spain). The platform is intended to be used for genotyping in Vir…

“Evaluation of a sequence-based method for hepatitis C genotyping (DeepChek® SingleRound PCR and NS5B/5’UTR sequencing) and comparison with VERSANT HCV Genotype 2.0 assay (InnoLiPA)” – Greet J. Boland et al. – EASL 2017 – See poster “Retreatment with Direct…

Advanced Biological Laboratories has been granted additional patents in Hong Kong (HK1121187) to further protect its intellectual property and reinforce the already existing core patent entitled ” Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications th…

Our team will provide information on our portfolio: Laboratories, virologists and microbiologists: DeepChek® Assays (Genotyping & Drug Resistance) UltraGene® Assays (Viral Load Detection) DeepChek®, SeqHepB® (Software systems for Sanger or NGS sequencing data management) Application: HBV, HCV… C…

Advanced Biological Laboratories (ABL) S.A. and Technogenetics (TGX) today announced that they entered into an exclusive distributor agreement of the DeepChek® SingleRound Assay and software product lines in Italy. The DeepChek® SingleRound Assay product line combines target-specific PCR reagents wi…

ABL continues developing its technology offer with Nadis(r) technology as a specialized patient management system. Nadis is widely used in France, this completes the offer for the French market in plus of microbiology reagents and software.